Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - May 2014


ADC Summit 2014 London

19 May 2014 - 20 May 2014 - London, UK



Bookmark and Share


Making your smart bomb smarter - creating innovative antibody-drug conjugates

SMi’s 3rd annual Antibody Drug Conjugates Summit comes at the perfect time to focus on innovative manufacturing techniques, preclinical and clinical data and next generation ADCs, bringing together key industry experts from academia, pharma and biotech companies.

Join us this May in London to hear case studies, presentations and round tables demonstrating how to maximise the therapeutic index of your ADC and how this form of empowered antibody is transforming next-generation antibody therapeutics. This must attend event will be delivered by true industry experts who will inform you of latest developments.

KEY REASONS TO ATTEND:

  • Hear cutting edge presentations and key case studies from leading ADCs experts on key topics such as nano-delivery systems, advancing preclinical development to accelerate ADCs into the clinic, next generation ADCs and manufacturing challenges
  • Network and learn from industry and academic opinion leaders including Photobiotics, Medlmmune, Spirogen, Synthon plus many more…
  • Learn about latest developments pertaining to the components of ADCs (payload, antibody and linker)
  • Join the debate in our round table session to discuss creative strategies in making the “smart bomb” more intelligent when building your oncology arsenal

KEY SPEAKERS WILL INCLUDE:

  • Dr Mahendra Deonarain, Chief Scientific Officer, Photobiotics
  • Dr Adeela Kamal, Associate Director, R&D, Oncology Research, MedImmune
  • Philip Howard, PhD, Chief Scientific Officer, Spirogen Limited
  • Dr Trevor Hallam, Chief Scientific Officer, Sutro Biopharma
  • Dr Ronald Elgersma, Project Leader, Antibody-Drug Conjugates, Synthon
  • Dr Erica Hong, Scientist, ImmunoGen
  • Dr Hagop Youssoufian, Executive Vice President of R&D, Progenics
  • Dr Pamela Trail, Vice President Oncology, Regeneron

This 2 day networking event will invite in depth discussion of key drivers impacting ADCs, providing a fantastic opportunity to hear from and talk to professionals currently operating in the market. 

To download a brochure and to secure your attendance visit http://www.smi-online.co.uk/goto/2014adcsummit36.asp 

Alternatively for further information contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk 



Further information
Scientific News
Unravelling the Metastatic Mechanism of Melanoma
Research has uncovered the mechanism of melanoma spreading; the findings could lead to a cure for the disease.
Gene Therapy Via Ultrasound
Research into a gene therapy approach called sonoporation could help combat heart disease and cancer.
Novel MRI Technique Distinguishes Healthy Prostate Tissue from Cancer
The UTSW researchers have determined that glucose stimulates release of the zinc ions from inside epithelial cells, which they could then track on MRIs.
Precision Nanobots Target Cancerous Tumours
Researchers achieve breakthrough toward redefining anti-cancer drug administration using nanorobotics.
PARP Proteins Explore Therapeutic Targets in Cancer
Researchers at UTSW have identified a previously unknown role of a certain class of proteins that opens the door to explore therapeutic targets in cancer and other disease.
Novel Therapeutic Approach for Blood Disorders
Gene editing of human blood-forming stem cells mimics a benign genetic condition that helps to overcome sickle cell disease and other blood disorders.
Immune-Cell Population Predicts Immunotherapy Response in Melanoma
All patients with high levels of one immune-cell type responded to treatment.
Effects of Chemotherapy on Developing Ovaries in Female Fetuses
Researchers at University of Edinburgh have shown that etoposide can damage the development of the ovaries while a fetus is in the womb.
Breast Tumors Evolve in Response to Hormone Therapy
Researchers have suggested that analyzing a single sample of the breast tumor is insufficient for understanding how a patient should best be treated.
Cutting off the Cancer Fuel Supply
Research from investigators at Rutgers Cancer Institute of New Jersey and Princeton University has identified a new approach to cancer therapy in cutting off a cancer cell’s ‘fuel supply’ by targeting a cellular survival mechanism known as autophagy. The co-corresponding authors of the work are Rutgers Cancer Institute Deputy Director Eileen P. White, PhD, and researcher ‘Jessie’ Yanxiang Guo, PhD.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!